MicroPort NeuroTech Limited
微創腦科學有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2172)

VOLUNTARY ANNOUNCEMENT
NUMEN® COIL EMBOLIZATION SYSTEM APPROVED FOR COMMERCIALIZATION IN JAPAN

This announcement is made by MicroPort NeuroTech Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed on the latest business development of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the NUMEN® Coil Embolization System (former Chinese name known as "NUMEN® 彈簧圈栓塞系統", the "**NUMEN®**") has been approved by the Japanese Ministry of Health, Labour and Welfare (the "**MHLW**") for final marketing authorisation. NUMEN® is independently developed by the Group as the new-generation electrolytic detachment coil and represents the first product of the Group approved for commercialization in Japan.

Japan is the world's third largest neuro-interventional market. Intracranial coil is classified as class IV high-risk special control medical device in Japan, and is subject to strict regulatory approval requirements. Leveraging on its design which fully addresses clinical needs and its outstanding performance demonstrated in verification tests, NUMEN®, as a neuro-interventional product independently developed, designed and manufactured by the Group, has been successfully recognized by relevant regulatory authorities in Japan.

According to the World Health Organization, stroke is currently the second leading cause of death worldwide. The intracranial aneurysm, the fatality rate and disability rate of which are extremely high once ruptured, is called an intracranial "untimed bomb". As a new-generation electrolytic detachment coil, NUMEN® is characterized by stable framing and dense packing. With its special microcircuit design of the pusher, electrolytic detachment of coils is made possible, shortening the operation time. The extremely-thin platinum and tungsten alloy wire and unique three-dimensional structure enable NUMEN® to be both flexible and supportive, minimizing pressure on the intracranial aneurysm wall and

ensuring the safety of embolization, and allows NUMEN® to be applied to the treatment of intracranial aneurysms of different shapes and provides physicians with a full range of solutions for the treatment of intracranial aneurysms.

NUMEN® and NUMEN FR® coil detachment system, after being approved for commercialization in China in 2020, have successively obtained CE Marking in the European Union, the Food and Drug Administration (FDA) approval in the United States, the Ministry of Food and Drug Safety (MFDS) approval in South Korea, and the Brazillian Health Surveillance Agency (ANVISA) approval in Brazil. Since its first overseas implantation completed in August 2021 in Chile, NUMEN® has been successfully commercialized in a number of countries in the Asia Pacific, North America and Europe. Its stable characteristic and excellent clinical performance have been fully recognized by physicians. The commercialization of NUMEN® in Japan is one of the Group's global strategic initiatives to continuously explore emerging markets. Moving forward, the Group will continue to devote itself to expanding the overseas market of neuro-interventional products, and providing more top-quality and comprehensive medical solutions of cerebral vessel diseases for patients and physicians worldwide.

By order of the Board
MicroPort NeuroTech Limited
Mr. Peng Bo
Chairman

Hong Kong, 26 August, 2022

As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Mr. Peng Bo, Mr. Wang Lin and Ms. Wu Xia as the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung as the independent non-executive directors.